25,729 articles
Hennepin County Medical Center
Hennepin County Medical Center (HCMC), also known as Hennepin Healthcare, is Minneapolis' public safety-net hospital and Level 1 trauma center, founded 1887 as Minneapolis City Hospital, county-owned since 1963, with Minnesota's largest emergency department.
Henoch–Schönlein purpura
Henoch–Schönlein purpura, now called IgA vasculitis (IgAV), is an immune complex small-vessel vasculitis causing palpable purpura, joint and abdominal symptoms, and kidney involvement, mostly in children aged 4–7.
Henri R. Manasse Jr.
Henri R. Manasse Jr. is an American pharmacy leader and medication-safety advocate, former chief executive officer of the American Society of Health-System Pharmacists and dean emeritus of the University of Illinois at Chicago College of Pharmacy.
Henrik H. Bendixen
Henrik H. Bendixen, also known as Henrik Holt Bendixen, was a Danish-born American anesthesiologist who chaired anesthesiology at Columbia and became its dean of medicine.
Henry Heimlich
Henry Heimlich, Cincinnati thoracic surgeon who invented the Heimlich maneuver (abdominal thrusts) for choking, published June 1974; later guidelines renamed it and added back blows first.
Henry Hugh Clutton
Henry Hugh Clutton (1850–1909) was an English surgeon at St Thomas's Hospital whose 1886 Lancet description of painless knee effusions in congenital syphilis gave medicine "Clutton's joints".
Henry Molaison
Henry Gustav Molaison (H.M., 1926–2008), American epilepsy patient whose 1953 bilateral medial temporal lobe resection caused profound amnesia; decades of study by Brenda Milner revealed distinct memory systems and the hippocampus's role.
Henry W. Foster Jr
Henry W. Foster Jr. (1933–2022) was an American obstetrician-gynecologist and medical educator at Meharry Medical College in Nashville, known for reducing infant mortality and his contested 1995 Surgeon General nomination.
Heparin
Heparin, a sulfated glycosaminoglycan anticoagulant discovered in 1916 by Jay McLean, potentiates antithrombin to inhibit thrombin and factor Xa; forms include unfractionated heparin and low-molecular-weight heparins, used for thrombosis, surgery, and dialysis, with recurring shortages tied to porcine sourcing.
Heparin-induced thrombocytopenia
Heparin-induced thrombocytopenia (HIT), an immune adverse reaction to heparin mediated by anti-PF4/heparin IgG, causes thrombocytopenia with paradoxical thrombosis; diagnosed via 4Ts score, immunoassays, and functional assays, and treated with non-heparin anticoagulants.
Hepatectomy
Hepatectomy, also called major hepatectomy, is surgery to remove part of the liver, classically three or more of its eight segments, with mortality now 2 to 3%.
HEPATHER study
ANRS CO22 HEPATHER, a French national prospective observational cohort launched August 2012 (NCT01953458), follows about 21,000 patients with hepatitis B or C to assess real-life treatment effectiveness, safety, and liver disease outcomes.
Hepatic arterial infusion
Hepatic arterial infusion is a regional chemotherapy method that infuses cytotoxic drugs through a catheter in the hepatic artery, mainly for unresectable colorectal liver metastases and cholangiocarcinoma.
Hepatic arteriovenous malformation
A hepatic arteriovenous malformation is a rare vascular malformation in which arteries connect directly to veins in the liver, causing heart failure, portal hypertension, and complications often present from birth.
Hepatic artery aneurysm
Hepatic artery aneurysm (HAA), true or pseudoaneurysm of the hepatic artery; about 20% of splanchnic aneurysms, incidence 0.002%-0.4%, 25% rupture risk, treated first by endovascular repair.
Hepatic artery embolization
Hepatic artery embolization, also called bland transarterial embolization, is an interventional radiology procedure that blocks arterial blood flow to kill liver tumors that cannot be surgically removed.
Hepatic cystic hamartoma
Hepatic cystic hamartoma, also called mesenchymal hamartoma of the liver, is a rare benign multicystic liver tumor of children under 2, treated by complete resection, with rare sarcomatous transformation.
Hepatic encephalopathy
Hepatic encephalopathy (HE), also called portosystemic encephalopathy, is a reversible neuropsychiatric syndrome of liver dysfunction graded by West Haven criteria, treated with lactulose and rifaximin.
Hepatic fibrosis or cirrhosis
Hepatic fibrosis is the buildup of scar tissue in the liver from chronic injury, and cirrhosis is its advanced stage, marked by regenerative nodules and fibrotic septa.
Hepatic haemorrhage
Hepatic hemorrhage is bleeding from the liver tissue or its vessels, most often caused by hepatocellular carcinoma. The spontaneous form is an acute surgical emergency.
Hepatic portal system
Hepatic portal system (portal venous system): veins draining the stomach, intestines, pancreas, spleen, and gallbladder into the hepatic portal vein, which supplies about 75% of liver blood flow before blood returns to the inferior vena cava.
Hepatic veno-occlusive disease
Hepatic veno-occlusive disease, or sinusoidal obstruction syndrome (SOS/VOD), is toxic sinusoidal endothelial injury causing nonthrombotic hepatic venular occlusion, mainly after HSCT conditioning or pyrrolizidine alkaloids, treated with defibrotide.
Hepaticogastrostomy
Hepaticogastrostomy is a procedure creating a connection between an intrahepatic bile duct and the stomach, usually performed endoscopically under ultrasound guidance to drain bile when ERCP fails, most often in malignant biliary obstruction.
Hepaticojejunostomy
Hepaticojejunostomy, also called the Rodney Smith operation when performed with transhepatic intubation, is a surgical operation connecting the hepatic bile duct to a Roux-en-Y jejunal limb to bypass strictures and repair bile duct injuries.
Hepatitis
Hepatitis: inflammation of the liver, mainly from viruses A through E. HBV (240 million chronic cases) and HCV (47 million) cause 95% of deaths; 1.3 million died in 2024; vaccines prevent A and B, drugs cure C.
Hepatitis A
Hepatitis A is an acute liver inflammation caused by the hepatitis A virus (HAV), a fecal-orally transmitted picornavirus. Distinguished from hepatitis B by its 28-day incubation, lack of chronicity, and preventability with vaccines licensed since 1995.
Hepatitis B
Hepatitis B, caused by the hepatitis B virus (HBV), a hepadnavirus, is a vaccine-preventable liver infection; 240 million chronic cases and 1.1 million deaths in 2024, vaccine since 1982.
Hepatitis B vaccine
Hepatitis B vaccine: recombinant HBsAg vaccine preventing HBV infection and liver cancer; first plasma-derived version 1981, recombinant 1986; birth dose recommended by WHO; US ACIP ended universal birth dose 2025.
Hepatitis C
Hepatitis C, liver inflammation caused by the bloodborne hepatitis C virus (HCV), formerly non-A, non-B hepatitis, identified in 1989; 47 million chronic infections, no vaccine, but direct-acting antivirals cure over 95% in 8–12 weeks.
Hepatitis C and HIV coinfection
HIV/HCV coinfection, simultaneous infection with HIV and hepatitis C virus, affects about 21% of US adults with HIV and up to 82% of those who inject drugs; HIV accelerates liver fibrosis, but direct-acting antivirals cure HCV in over 94% of coinfected patients.